Introduction: This study aimed to compare the efficacy of first-line nedaplatin (80 mg/m
Introduction
Lung cancer is a leading cause of cancer morbidity and mortality, with a 5-year survival rate of merely 18%. 1 More than 85% of lung cancers are NSCLC, which is subdivided into lung adenocarcinoma (LADC), lung squamous cell carcinoma (LSQCC), and large-cell carcinoma. 2 Recently, drugs targeting EGFR mutations and ALK receptor tyrosine kinase (ALK) and ROS1 rearrangements have improved the outcomes of patients with LADC and highlight the importance of molecular and genomic profiling and subtyping of lung tumors. [3] [4] [5] [6] [7] [8] Nevertheless, compared with LADC, only a few druggable genomic alterations have been found for LSQCC, resulting in poor outcomes. 9 For patients with LSQCC, palliative chemotherapy (e.g., cisplatin with docetaxel, paclitaxel, vinorelbine, irinotecan, or gemcitabine) is considered to be an effective first-line treatment, but this approach has limited efficacy and serious side effects. 10 For the treatment of LSQCC, cytotoxic chemotherapy is commonly used in clinic, as well as immunotherapy. 11 Among the classical cytotoxic chemotherapy regimens, cisplatin-containing regimens are routinely used, but they are associated with significant severe adverse events such as neurotoxicity, nephrotoxicity, nausea, and vomiting. [11] [12] [13] Nedaplatin is a cisplatin analog and has been developed as an alternative to cisplatin, with less toxicity. 10, 14, 15 Nedaplatin has the same two amine carrier ligands as cisplatin, which can react with nucleosides to form nucleoside-platinum complexes.
14 It has been suggested that the binding of the active species to DNA results in the inhibition of DNA synthesis and duplication upon nedaplatin treatment, identical to that observed with cisplatin. 16 Thus, the application of nedaplatin in patients with cancer ultimately leads to irreversible cell death and consequently results in favorable anticancer responses. Indeed, a previous phase III trial in Japan showed that the combination of nedaplatin with docetaxel improved the overall survival of patients with advanced or relapsed LSQCC compared with cisplatin plus docetaxel, but they used docetaxel at 60 mg/m 2 and cisplatin at 80 mg/m 2 , which are not standard doses used worldwide. 10, 17 Nevertheless, the efficacy and safety of the combination therapy of nedaplatin with docetaxel on progression-free survival (PFS) remain unclear, especially when using standard doses of docetaxel and cisplatin. 
Methods

Participants
This was a randomized phase III trial performed at 12 hospitals in China. Between December 2013 and December 2015, the participants with LSQCC confirmed by pathologic examination were screened for eligibility. The exclusion criteria were: 1) sputum cytology; or 2) stage IIIb (fit for radiation therapy) of LSQCC, as defined by the Union for International Cancer Control TNM classifications (IASLC 2009).
Additional exclusion criteria were: 1) history of brain metastases, treated or not, confirmed by magnetic resonance imaging or enhanced computed tomography; 2) any other cancer in the previous 5 years, except cured skin basal cell carcinoma and cervical carcinoma in situ; 3) previous therapy for the primary lesion (except for bisphosphonates); 4) serious uncontrolled systemic disease such as active infections, uncontrolled hypertension, diabetes, unstable angina, congestive heart failure, myocardial infarction (within 1 year before initiation of treatment) or severe arrhythmia requiring medication; or 5) pregnancy and lactation.
The study protocol was approved by ethics committee of the Shanghai Chest Hospital and each of the 12 participating hospitals. All patients provided written informed consent.
Randomization and Blinding
A total of 286 patients were enrolled at participating institutions. All eligible patients were randomized to receive nedaplatin plus docetaxel (142 patients) or cisplatin plus docetaxel (144 patients).
Procedures and Intervention
Docetaxel (75 mg/m 2 ) was administered on the first day of each chemotherapy cycle (one cycle was 3 weeks). The nedaplatin group received 80 mg/m 2 nedaplatin and the infusion time was not less than 1 hour. The control group was administered cisplatin (75 mg/m 2 ) infusion, which was completed within 3 hours. The infusion was administered the first day of each cycle, for four cycles. In principle, the therapy had to be completed or could be ceased in cases of unequivocal disease progression, diagnosis with secondary malignancy, patients' request, and investigators' belief that chemotherapy was not beneficial or could harm the patient.
Outcomes
The primary endpoint was PFS, which was defined as the time from the date of randomization to the date of documented disease progression or death. 18 Progression was defined according to the Response Evaluation Criteria in Solid Tumors version 1.1. Imaging was performed every 6 weeks and was analyzed at each participating center. The secondary endpoints included the overall response rate, which represented the percentage of patients with reduced tumor burden in a predefined amount. 19 In contrast, the disease control rate (DCR) was the proportion of patients who showed a complete treatment response, a partial treatment response, or stable disease. 19 Time to progression (TTP) was calculated as the time from randomization to objective tumor progression, but cancer death was not included. 18 The lung cancer symptom scale was used to evaluate the health-related quality of life and functional dimensions of life. 20 The proportions of patients with cancer with measurable lesions achieving a response were assessed according to Response Evaluation Criteria in Solid Tumors version 1.1. 19 Alive patients without any event were censored at the end of follow-up (August 15, 2016). Subjects who withdrew for any reason were censored on the withdrawal date. The drug adverse events were assessed according to the National Cancer Institute's Common Terminology Criteria (version 3.0).
Statistical Analysis
PFS of the control group (docetaxel plus cisplatin) is approximately 4 months. [21] [22] [23] We aimed to improve the PFS of docetaxel (75 mg/m 2 ) and nedaplatin (80 mg/ m 2 ) to 5.5 months (1.5 months improvement compared with docetaxel plus cisplatin), but with as few neutropenia events as possible. 24 Thus, the number for each group was 130 and finally the size was 143 considering a 10% drop-out rate. Considering the risk of progression in the nedaplatin group relative to that of the control group, a two-sided a of 0.05 and b of 20% were used to calculate a hazard ratio of 0.7 between groups, according to a previous study. 24 On the basis of this assumption, the enrollment period was 12 months accompanied by 18 months of follow-up.
The intent-to-treat (ITT) analysis was based on the treatment originally assigned to each patient. The primary efficacy endpoints and adverse events were analyzed in the ITT population, excluding patients who did not complete the treatment protocol.
For PFS estimation, the Kaplan-Meier method was used to estimate the survival curves of the two groups. The log-rank test was used to assess the proportional hazards assumption graphically. Long-term benefits were estimated using the Cox regression model, considering 95% confidence interval (CI). The overall response to chemotherapy was calculated in the ITT population and the percentage of patients who achieved a response and disease control was compared between the two groups using Fisher's exact test. All analyses were performed using SAS 9.4 (SAS Institute, Cary, North Carolina). This trial was registered (ClinicalTrial.gov #NCT02088515).
Results
Enrollment
From December 2013 to December 2015, 286 patients were enrolled from 12 hospitals and randomly assigned to the nedaplatin plus docetaxel (n ¼ 142) or cisplatin plus docetaxel (n ¼ 144) group (Fig. 1) . One patient in the nedaplatin group and five in the cisplatin group withdrew before treatment and were excluded from further analyses (Fig. 1) .
Characteristics of the Patients
The baseline characteristics of the patients were well balanced between the two groups ( Table 1 ). In the ITT set, the median number of treatment cycles in the cisplatin group was higher than that in the nedaplatin group (3.7 ± 0.8 versus 3.3 ± 1.0, p ¼ 0.0015). There was no difference in drug dose between the two groups ( Table 2) .
Follow-Up
The median follow-up of the 280 patients in the modified ITT population was determined. Median PFS was 4.63 months (95% CI: 4.43-5.10) in the nedaplatin group and 4.23 months (95% CI: 3.37-4.53) in the cisplatin group, without difference between the two groups (log-rank test, p ¼ 0.056) (Fig. 2A) .
No significant difference in TTP was observed between the two groups in the ITT set (Fig. 2B) . In addition, the best overall response was better among the 133 patients in the nedaplatin group compared with the 128 patients in the cisplatin group (51.5% versus 38.1%, p ¼ 0.034), and the DCR was also better (96.2% versus 82.5%, p ¼ 0.0004) ( Table 3) .
Adverse Events
Grade 3 or 4 adverse events were observed in 46 (32.6%) of the 141 patients in the nedaplatin group and 62 (44.6%) of the 139 in the cisplatin group. No grade 5 adverse event was observed. Table 4 shows adverse events with a frequency of more than 5%.
There were no differences in the occurrence of leucopenia and neutropenia between the two groups (all p > 0.05). Any-grade anemia was less frequent in the nedaplatin group (36.9% versus 49.6%, p ¼ 0.031), whereas any-grade thrombocytopenia was more frequent in the nedaplatin group (19.1% versus 10.8%, p ¼ 0.049). Grade 3 or worse thrombocytopenia was similar in the two groups (2.8% versus 2.2%, p ¼ 0.716).
Grade 3 or worse adverse events of nausea and vomiting were less frequent in the nedaplatin group than in the cisplatin group (0% versus 5.0%, p ¼ 0.002). Anygrade adverse events of nausea and vomiting (29.1% versus 59.0%, p < 0.001), fatigue (27.0% versus 38.8%, p ¼ 0.034), and renal injury (creatinine: 3.5% versus 9.4%, p ¼ 0.044; urea nitrogen: 2.1% versus 11.5%, p ¼ 0.001) were less frequent in the nedaplatin than in the cisplatin groups (Table 4) .
Discussion
Data about standard-dose cisplatin plus docetaxel versus nedaplatin plus docetaxel on PFS and TTP in patients with LSQCC carcinoma are limited. A phase II trial showed improved PFS to 7.4 months with docetaxel and nedaplatin, but the high dose of nedaplatin (100 mg/ m 2 ) resulted in severe neutropenia. 24 Thus, we aimed to improve the PFS of docetaxel (75 mg/m 2 ) and nedaplatin (80 mg/m 2 ) compared with docetaxel plus cisplatin while reducing the occurrence of neutropenia events as much as possible. 3 Therefore, this phase III trial aimed to compare PFS and safety associated with the use of 80 mg/m 2 nedaplatin plus 75 mg/m 2 docetaxel versus cisplatin 75 mg/m 2 plus docetaxel 75 mg/m 2 for treating advanced LSQCC. The results showed that the combination of nedaplatin with docetaxel did not prolong PFS. The overall response rate and DCR were better in the nedaplatin group than in the cisplatin group, but no significant difference in TTP was observed. In addition, several important grade III or IV adverse events (leucopenia, neutropenia, anemia, nausea, and vomiting) were less common and milder in the nedaplatin group than that in the cisplatin group. Taken together, these results suggested that nedaplatin plus docetaxel was not associated with better PFS, but with a better disease control rate and with less adverse events. Note: Data are n (%), unless otherwise specified.
This study used standard doses used worldwide, compared with a previous study that used lower doses docetaxel. 3, 10 The most adequate dose of nedaplatin is still controversial. In the WJOG 5208L trial, nedaplatin (100 mg/m 2 ) treatment showed a high frequency of grade 3-4 thrombocytopenia, almost up to 9%, whereas a phase II trial of nedaplatin (100 mg/m 2 ) showed that the frequency of grade 3-4 neutropenia was 86%. 10, 24 It was suggested that the incidence of thrombocytopenia was closely related to the dose of nedaplatin. Therefore, nedaplatin 80 mg/m 2 was chosen in the present study to reduce toxicity. In the WJOG 5208L trial, docetaxel 60 mg/m 2 was used, which is lower than the dose used in Europe and North America (75 mg/m 2 ). 17 Therefore, standard docetaxel 75 mg/m 2 was used in the present study. Imaging evaluation showed that the majority of patients had very good control of tumor growth. Thus, the combination of nedaplatin (80 mg/m 2 ) with docetaxel (75 mg/m 2 ) could be appropriate for the treatment of LSQCC.
Generally, previous studies have shown that most PFS events occurred in the first 6 months, but in the present study, four 3-week cycles were given, representing 3 months of treatment, which was shorter than in the WJOG 5208L trial. 10, 11, 15, 25 In the present study, there was no significant difference in PFS between groups using the ITT set. Therefore, the response might be associated with the number of treatments, but additional studies are necessary to examine this point.
The combination of cisplatin with other chemotherapeutic drugs (e.g., docetaxel, irinotecan, paclitaxel, gemcitabine, or vinorelbine) is the standard first-line treatment for patients with LSQCC, but relief from pain and other symptoms is associated with toxicity. 11 It was reported that 123 Italian patients with 11 different tumor types receiving cisplatin were more likely to suffer from serious adverse effects (72%) such as gastrointestinal adverse effects (gastroenterological and adnexal glands) and constitutional symptoms (asthenia, hyposthenia, weight loss, etc.). 26 In the present study, more anemia and worse anorexia and fatigue were found in the cisplatin group, which may be the result of severe nausea or vomiting and renal function impairment, but less adverse events were observed in the nedaplatin group than in the cisplatin group. In the present study, a lower rate of neutropenia was observed with nedaplatin compared with cisplatin. The rate of grade 3 or greater thrombocytopenia was similar in the two groups. Nevertheless, probably because of the lower dose, the rate of thrombocytopenia was lower than in the WJOG 5208L trial. 10 This study has some limitations. Of course, statistical handling might affect the results and only the ITT analysis was used in the present study. 27, 28 Although it yielded negative results, it nevertheless suggests that both treatments could be appropriate in those patients. In addition, only PFS was examined, which could be accepted as a universal primary endpoint in patients with lung cancer, making the statistical handling independent of the primary treatment and other potential causes of cancer deaths. 29 Finally, imaging was analyzed at each participating center, not centrally, which could have introduced some bias.
In conclusion, there is no improvement in PFS with the nedaplatin and docetaxel combination in the ITT analysis. More hematologic toxicities were observed in the nedaplatin plus docetaxel group (compared with cisplatin plus docetaxel), whereas more nonhematologic toxicities were observed in the cisplatin plus docetaxel group. Nedaplatin plus docetaxel could be a new treatment option for advanced or relapsed LSQCC patients. Further investigation is needed to elucidate the underlying mechanisms and explore possible biomarkers for the efficacy evaluations of the drugs.
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